Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — Jefferies London Healthcare Conference 2024

11 slides from Abcellera Biologics's conference presentation, Nov 19, 2024

  1. Slide 1: Jefferies London Healthcare Conference 2024

    Jefferies London Healthcare Conference 2024 COPYRIGHT © ABCELLERA November 19, 2024

  2. Slide 2: Disclaimer

    DISCLAIMER Jefferies London Healthcare Conference This presentation contains forward-looking statements, including statements made These statements involve risks, uncertainties and other factors that may cause pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act act

  3. Slide 3: We are a biotech with the ability to make many antibody medicines

    We are a biotech with the ability to make Jefferies London Healthcare Conference many antibody TECHNOLOGY TEAM medicines. THE ENGINE By integrating computation, engineering and biology, we have built a vertically integrated biotech that is capable of developing differentiated antibody-based therapie

  4. Slide 4: We built our engine through partnerships

    100+ 14 We built our partnered-initiated molecules from partnered therapeutic programs programs have reached the clinic engine through Jefferies London Healthcare Conference partnerships. AbbVie Since 2014, we have partnered with some of the industry’s most innovative pharma and biotech companies. P

  5. Slide 5: We have a portfolio of royalties in future antibody medicines

    We have a portfolio of royalties in future antibody medicines. Jefferies London Healthcare Conference Cumulative # of Cumulative # of PARTNER-INITIATED PROGRAM STARTS MOLECULES IN THE CLINIC* WITH DOWNSTREAMS* The value of this portfolio will mature over time as our partners advance these programs i

  6. Slide 6: We are now using our engine to build an internal pipeline

    We are now using our engine to build an internal pipeline of potential blockbuster medicines. Jefferies London Healthcare Conference Clinical manufacturing facility Capital allocation shifting 12+ years on-track to come online late 2025 from building capabilities to using them investment in technolo

  7. Slide 7: We have the liquidity to execute on our strategy

    We have the ~$875M in available liquidity to execute on capability and Jefferies London Healthcare Conference our strategy capital to execute on our strategy. ~$670M in total cash, cash equivalents, & marketable securities Through our partnership work, revenue from COVID, and committed government fu

  8. Slide 8: We're hunting for blockbusters and are not limited to a single indication

    We’re hunting for Do we like the science? blockbusters and are not limited to Jefferies London Healthcare Conference Is there a commercial opportunity a single indication. with an unmet medical need? What’s most important now is which programs we pick. Our engine can be applied broadly to the Is the

  9. Slide 9: We intend to submit Clinical Trial Applications for our first 2 programs

    We intend to submit Clinical Trial Applications * for our first 2 programs in Q2 2025. Jefferies London Healthcare Conference MOLECULE TARGET INDICATION THERAPEUTIC AREA POTENTIAL STAGE DIFFERENTIATION ABCL635 undisclosed undisclosed metabolic & first in class IND-ENABLING GPCR or endocrine conditions

  10. Slide 10: 2025 Q2 On-Track

    2025 Q2 On-Track First 2 1-3 INDs We expect a CTAs * per year Jefferies London Healthcare Conference number of for ABCL635, ABCL575 over next key milestones 5 years in the next 18 2026 ● 20+ internal programs First 2 in the pipeline to 24 months. Readouts ● Expect steady flow of readouts on potential

  11. Slide 11: Thank You

    11 COPYRIGHT © ABCELLERA Jefferies London Healthcare Conference THANK YOU

AbCellera Biologics — Jefferies London Healthcare Conference 2024 on 6ix